Capricor Therapeutics, Inc. (CAPR)
CAPR Stock Price Chart
Explore Capricor Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CAPR price movements and trends.
CAPR Company Profile
Discover essential business fundamentals and corporate details for Capricor Therapeutics, Inc. (CAPR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Feb 2007
Employees
231.00
Website
https://www.capricor.comCEO
Linda Marbán
Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR Financial Timeline
Browse a chronological timeline of Capricor Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.58, while revenue estimate is $2.08m.
Earnings released on 12 May 2026
EPS came in at -$0.59 falling short of the estimated -$0.55 by -7.27%.
Earnings released on 12 Mar 2026
EPS came in at -$0.62 falling short of the estimated -$0.51 by -21.57%.
Earnings released on 10 Nov 2025
EPS came in at -$0.54 matching the estimated -$0.54.
Earnings released on 11 Aug 2025
EPS came in at -$0.57 falling short of the estimated -$0.48 by -18.75%.
Earnings released on 13 May 2025
EPS came in at -$0.53 falling short of the estimated -$0.33 by -60.61%.
Earnings released on 19 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.31 by +48.39%, while revenue for the quarter reached $11.13m , beating expectations by +102.37%.
Earnings released on 13 Nov 2024
EPS came in at -$0.38 falling short of the estimated -$0.36 by -5.56%, while revenue for the quarter reached $2.26m , missing expectations by -77.09%.
Earnings released on 7 Aug 2024
EPS came in at -$0.35 surpassing the estimated -$0.36 by +2.78%, while revenue for the quarter reached $3.97m , beating expectations by +10.93%.
Earnings released on 13 May 2024
EPS came in at -$0.31 falling short of the estimated -$0.11 by -181.82%, while revenue for the quarter reached $4.91m , missing expectations by -49.41%.
Earnings released on 29 Feb 2024
EPS came in at -$0.02 surpassing the estimated -$0.09 by +77.78%, while revenue for the quarter reached $12.09m , beating expectations by +14.04%.
Earnings released on 14 Nov 2023
EPS came in at -$0.25 surpassing the estimated -$0.29 by +13.79%, while revenue for the quarter reached $6.19m , missing expectations by -43.25%.
Earnings released on 7 Aug 2023
EPS came in at -$0.29 surpassing the estimated -$0.35 by +17.14%, while revenue for the quarter reached $3.92m , beating expectations by +161.16%.
Earnings released on 11 May 2023
EPS came in at -$0.31 surpassing the estimated -$0.32 by +3.13%, while revenue for the quarter reached $2.99m , beating expectations by +497.34%.
Earnings released on 15 Mar 2023
EPS came in at -$0.31 surpassing the estimated -$0.33 by +6.06%, while revenue for the quarter reached $959.90k , beating expectations by +9.50k%.
Earnings released on 10 Nov 2022
EPS came in at -$0.26 surpassing the estimated -$0.29 by +10.34%, while revenue for the quarter reached $1.59m , beating expectations by +278.94%.
Earnings released on 10 Aug 2022
EPS came in at -$0.29 falling short of the estimated -$0.25 by -16.00%.
Earnings released on 10 May 2022
EPS came in at -$0.32 .
Earnings released on 10 Mar 2022
EPS came in at -$0.26 falling short of the estimated -$0.19 by -36.84%, while revenue for the quarter reached -$244.65k .
Earnings released on 9 Nov 2021
EPS came in at -$0.17 surpassing the estimated -$0.22 by +22.73%.
Earnings released on 12 Aug 2021
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%, while revenue for the quarter reached $204.08k , missing expectations by -8.00%.
CAPR Stock Performance
Access detailed CAPR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
